Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of delays in drugs reimbursability in different countries and because some National Health Systems identify only patients with advanced disease as a treatment priority. Italy in this regard is a prototype about DAAs treatment of CHC patients. With the aim to assess the Italian treatment experience with DAAs and to respond to unmet needs in treatment optimization of antiviral therapy in specific settings of CHC patients, a group of Italian experts met in Stresa in February 2017. The summary of the considerations arising from this two-day meeting and some statements regarding a few open issues are reported in this position paper.

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel / Viganò, Mauro; Perno, Carlo Federico; Aghemo Alessio, Alberti Alfredo, Andreone Pietro, Andreoni Massimo, Bonora Stefano, Brunetto Maurizia Rossana, Bruno Raffaele, Bruno Savino, Calvaruso Vincenza, Caporaso Nicola, Ceccherini-Silberstein Francesca, Cento Valeria, Ciancio Alessia, Colombatto Piero, Degasperi Elisabetta, Di Marco Vito, Di Perri Giovanni, D'offizi Giampiero, Fagiuoli Stefano, Ferrari Carlo, Gaeta Giovanni Battista, Pellicelli Adriano, Petta Salvatore, Piovesan Sara, Puoti Massimo, Raimondo Giovanni, Russo Francesco Paolo, Taliani Gloria, Trama U23, Villa Erica, Zignego Anna Linda, Craxì, Antonio,. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 49:(2017), pp. 731-741. [10.1016/j.dld.2017.03.027]

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

Caporaso Nicola;Ferrari Carlo;Russo Francesco Paolo;Taliani Gloria;Zignego Anna Linda;
2017

Abstract

Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of delays in drugs reimbursability in different countries and because some National Health Systems identify only patients with advanced disease as a treatment priority. Italy in this regard is a prototype about DAAs treatment of CHC patients. With the aim to assess the Italian treatment experience with DAAs and to respond to unmet needs in treatment optimization of antiviral therapy in specific settings of CHC patients, a group of Italian experts met in Stresa in February 2017. The summary of the considerations arising from this two-day meeting and some statements regarding a few open issues are reported in this position paper.
49
731
741
Goal 3: Good health and well-being
Viganò, Mauro; Perno, Carlo Federico; Aghemo Alessio, Alberti Alfredo, Andreone Pietro, Andreoni Massimo, Bonora Stefano, Brunetto Maurizia Rossana, Bruno Raffaele, Bruno Savino, Calvaruso Vincenza, Caporaso Nicola, Ceccherini-Silberstein Francesca, Cento Valeria, Ciancio Alessia, Colombatto Piero, Degasperi Elisabetta, Di Marco Vito, Di Perri Giovanni, D'offizi Giampiero, Fagiuoli Stefano, Ferrari Carlo, Gaeta Giovanni Battista, Pellicelli Adriano, Petta Salvatore, Piovesan Sara, Puoti Massimo, Raimondo Giovanni, Russo Francesco Paolo, Taliani Gloria, Trama U23, Villa Erica, Zignego Anna Linda, Craxì, Antonio,
File in questo prodotto:
File Dimensione Formato  
ELSEVIER 2017.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 813.58 kB
Formato Adobe PDF
813.58 kB Adobe PDF Visualizza/Apri

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1170827
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact